BioNTech Historical Financial Ratios

BNTX Stock

USD 113.13 4.90 4.53%

BioNTech is presently reporting on over 122 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Dividend Yield of 0.0111, PTB Ratio of 1.2 or Days Sales Outstanding of 235 will help investors to properly organize and evaluate BioNTech SE financial condition quickly.

Quick Ratio Current Ratio

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BioNTech SE. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

About BioNTech Financial Ratios Analysis

BioNTech SEFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate BioNTech investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on BioNTech financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across BioNTech history.

BioNTech Financial Ratios Chart

At this time, BioNTech's POCF Ratio is fairly stable compared to the past year. Capex To Operating Cash Flow is likely to rise to 0.14 in 2024, whereas Price To Sales Ratio is likely to drop 5.77 in 2024.

Price To Sales Ratio Dividend Yield Days Sales Outstanding Invested Capital Ev To Sales Return On Tangible Assets

Add Fundamental

Price To Sales Ratio

Price to Sales Ratio is figured by comparing BioNTech SE stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on BioNTech sales, a figure that is much harder to manipulate than other BioNTech SE multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.

Dividend Yield

Dividend Yield is BioNTech SE dividend as a percentage of BioNTech stock price. BioNTech SE dividend yield is a measure of BioNTech stock productivity, which can be interpreted as interest rate earned on an BioNTech investment. A financial ratio that shows how much a company pays out in dividends each year relative to its stock price, calculated as annual dividends per share divided by price per share.

Invested Capital

Invested capital represents the total cash investment that shareholders and debt holders have contributed to BioNTech SE. There are two different methods for calculating BioNTech SE invested capital: operating approach and financing approach. Understanding BioNTech invested capital allows investors to calculate measures of performance such as return on invested capital or return on capital employed.

Ev To Sales

The Enterprise Value to Sales ratio, a valuation metric used to compare the value of a company, including debt and excluding cash, to its sales revenue.

Return On Tangible Assets

A profitability metric that measures a company's ability to generate earnings from its tangible assets.

Most ratios from BioNTech's fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into BioNTech SE current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BioNTech SE. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

	2023	2024 (projected)
Dividend Yield	0.0125	0.0111
Price To Sales Ratio	6.07	5.77

Dividend Yield Price To Sales Ratio

BioNTech fundamentals Correlations

	Price To Sales Ratio	Dividend Yield	Ptb Ratio	Days Sales Outstanding	Book Value Per Share	Free Cash Flow Yield	Operating Cash Flow Per Share	Capex To Depreciation	Pb Ratio	Ev To Sales	Free Cash Flow Per Share	Roic	Inventory Turnover	Net Income Per Share	Days Of Inventory On Hand	Payables Turnover	Capex To Revenue	Cash Per Share	Pocfratio	Interest Coverage	Payout Ratio	Capex To Operating Cash Flow	Pfcf Ratio	Days Payables Outstanding	Income Quality	Roe
Price To Sales Ratio		0.53	-0.61	-0.57	-0.89	-0.78	-0.72	0.53	-0.61	1.0	-0.7	0.4	0.81	-0.7	-0.65	-0.5	0.87	-0.78	-0.1	-0.59	0.53	-0.28	-0.43	0.29	-0.52	0.49
Dividend Yield	0.53		-0.33	-0.48	-0.71	-0.53	-0.39	0.18	-0.33	0.55	-0.35	0.41	0.7	0.05	-0.94	0.21	0.43	-0.8	-0.14	0.05	1.0	-0.3	-0.21	-0.33	-0.93	0.41
Ptb Ratio	-0.61	-0.33		0.87	0.57	0.49	0.42	-0.97	1.0	-0.63	0.41	-0.93	-0.67	0.42	0.43	0.57	-0.87	0.5	-0.25	0.38	-0.33	-0.05	0.02	-0.72	0.37	-0.96
Days Sales Outstanding	-0.57	-0.48	0.87		0.66	0.5	0.39	-0.88	0.87	-0.58	0.37	-0.77	-0.85	0.42	0.59	0.54	-0.86	0.58	-0.28	0.45	-0.48	-0.03	0.06	-0.57	0.45	-0.82
Book Value Per Share	-0.89	-0.71	0.57	0.66		0.92	0.84	-0.47	0.57	-0.9	0.82	-0.44	-0.9	0.59	0.81	0.42	-0.81	0.96	0.2	0.4	-0.71	0.43	0.45	-0.17	0.73	-0.51
Free Cash Flow Yield	-0.78	-0.53	0.49	0.5	0.92		0.98	-0.39	0.49	-0.79	0.97	-0.39	-0.75	0.58	0.61	0.43	-0.72	0.92	0.13	0.21	-0.53	0.33	0.27	-0.23	0.59	-0.45
Operating Cash Flow Per Share	-0.72	-0.39	0.42	0.39	0.84	0.98		-0.33	0.42	-0.72	1.0	-0.32	-0.63	0.61	0.47	0.48	-0.65	0.84	0.18	0.2	-0.39	0.35	0.28	-0.27	0.46	-0.37
Capex To Depreciation	0.53	0.18	-0.97	-0.88	-0.47	-0.39	-0.33		-0.97	0.54	-0.33	0.83	0.61	-0.51	-0.27	-0.7	0.85	-0.35	0.3	-0.5	0.18	0.11	-0.02	0.84	-0.17	0.88
Pb Ratio	-0.61	-0.33	1.0	0.87	0.57	0.49	0.42	-0.97		-0.63	0.41	-0.93	-0.67	0.42	0.43	0.57	-0.87	0.5	-0.25	0.38	-0.33	-0.05	0.02	-0.72	0.37	-0.96
Ev To Sales	1.0	0.55	-0.63	-0.58	-0.9	-0.79	-0.72	0.54	-0.63		-0.7	0.44	0.82	-0.68	-0.67	-0.48	0.87	-0.8	-0.1	-0.56	0.55	-0.29	-0.43	0.29	-0.56	0.52
Free Cash Flow Per Share	-0.7	-0.35	0.41	0.37	0.82	0.97	1.0	-0.33	0.41	-0.7		-0.3	-0.6	0.62	0.42	0.49	-0.64	0.81	0.17	0.2	-0.35	0.34	0.27	-0.29	0.42	-0.35
Roic	0.4	0.41	-0.93	-0.77	-0.44	-0.39	-0.32	0.83	-0.93	0.44	-0.3		0.53	-0.08	-0.47	-0.27	0.68	-0.48	0.26	-0.02	0.41	0.08	0.14	0.52	-0.5	0.99
Inventory Turnover	0.81	0.7	-0.67	-0.85	-0.9	-0.75	-0.63	0.61	-0.67	0.82	-0.6	0.53		-0.5	-0.83	-0.41	0.88	-0.84	0.13	-0.45	0.7	-0.12	-0.21	0.25	-0.66	0.6
Net Income Per Share	-0.7	0.05	0.42	0.42	0.59	0.58	0.61	-0.51	0.42	-0.68	0.62	-0.08	-0.5		0.07	0.92	-0.68	0.35	0.2	0.87	0.05	0.33	0.56	-0.64	-0.09	-0.19
Days Of Inventory On Hand	-0.65	-0.94	0.43	0.59	0.81	0.61	0.47	-0.27	0.43	-0.67	0.42	-0.47	-0.83	0.07		-0.1	-0.56	0.87	0.11	0.07	-0.94	0.3	0.25	0.24	0.95	-0.48
Payables Turnover	-0.5	0.21	0.57	0.54	0.42	0.43	0.48	-0.7	0.57	-0.48	0.49	-0.27	-0.41	0.92	-0.1		-0.67	0.18	0.04	0.8	0.21	0.18	0.38	-0.87	-0.23	-0.36
Capex To Revenue	0.87	0.43	-0.87	-0.86	-0.81	-0.72	-0.65	0.85	-0.87	0.87	-0.64	0.68	0.88	-0.68	-0.56	-0.67		-0.69	0.21	-0.59	0.43	-0.02	-0.17	0.62	-0.41	0.76
Cash Per Share	-0.78	-0.8	0.5	0.58	0.96	0.92	0.84	-0.35	0.5	-0.8	0.81	-0.48	-0.84	0.35	0.87	0.18	-0.69		0.16	0.11	-0.8	0.37	0.29	0.0	0.85	-0.52
Pocfratio	-0.1	-0.14	-0.25	-0.28	0.2	0.13	0.18	0.3	-0.25	-0.1	0.17	0.26	0.13	0.2	0.11	0.04	0.21	0.16		0.17	-0.14	0.97	0.88	0.27	0.25	0.25
Interest Coverage	-0.59	0.05	0.38	0.45	0.4	0.21	0.2	-0.5	0.38	-0.56	0.2	-0.02	-0.45	0.87	0.07	0.8	-0.59	0.11	0.17		0.05	0.27	0.6	-0.56	-0.15	-0.13
Payout Ratio	0.53	1.0	-0.33	-0.48	-0.71	-0.53	-0.39	0.18	-0.33	0.55	-0.35	0.41	0.7	0.05	-0.94	0.21	0.43	-0.8	-0.14	0.05		-0.3	-0.21	-0.33	-0.93	0.41
Capex To Operating Cash Flow	-0.28	-0.3	-0.05	-0.03	0.43	0.33	0.35	0.11	-0.05	-0.29	0.34	0.08	-0.12	0.33	0.3	0.18	-0.02	0.37	0.97	0.27	-0.3		0.92	0.15	0.4	0.06
Pfcf Ratio	-0.43	-0.21	0.02	0.06	0.45	0.27	0.28	-0.02	0.02	-0.43	0.27	0.14	-0.21	0.56	0.25	0.38	-0.17	0.29	0.88	0.6	-0.21	0.92		0.0	0.25	0.08
Days Payables Outstanding	0.29	-0.33	-0.72	-0.57	-0.17	-0.23	-0.27	0.84	-0.72	0.29	-0.29	0.52	0.25	-0.64	0.24	-0.87	0.62	0.0	0.27	-0.56	-0.33	0.15	0.0		0.32	0.58
Income Quality	-0.52	-0.93	0.37	0.45	0.73	0.59	0.46	-0.17	0.37	-0.56	0.42	-0.5	-0.66	-0.09	0.95	-0.23	-0.41	0.85	0.25	-0.15	-0.93	0.4	0.25	0.32		-0.49
Roe	0.49	0.41	-0.96	-0.82	-0.51	-0.45	-0.37	0.88	-0.96	0.52	-0.35	0.99	0.6	-0.19	-0.48	-0.36	0.76	-0.52	0.25	-0.13	0.41	0.06	0.08	0.58	-0.49

Click cells to compare fundamentals

BioNTech Account Relationship Matchups

BioNTech fundamentals Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Price To Sales Ratio	58.84	32.56	2.91	1.97	6.07	5.77
Ptb Ratio	12.95	11.45	4.65	1.7	1.15	1.2
Book Value Per Share	2.33	5.83	48.74	82.43	83.35	87.52
Free Cash Flow Yield	(0.0422)	(0.006299)	0.0133	0.39	0.2	0.21
Operating Cash Flow Per Share	(0.94)	(0.0572)	3.65	55.81	22.11	23.22
Stock Based Compensation To Revenue	0.28	0.0666	0.004948	0.006274	0.0135	0.0128
Capex To Depreciation	2.1	2.21	2.05	2.95	3.85	3.41
Pb Ratio	12.95	11.45	4.65	1.7	1.15	1.2
Ev To Sales	54.7	30.55	2.84	1.18	3.08	2.92
Free Cash Flow Per Share	(1.27)	(0.42)	3.02	54.31	19.21	20.17
Roic	(0.37)	0.00533	0.86	0.46	0.0265	0.0251
Inventory Turnover	20.8	10.99	7.68	10.31	1.68	1.59
Net Income Per Share	(0.85)	0.0646	42.18	38.78	3.83	3.64
Days Of Inventory On Hand	17.55	33.23	47.51	35.4	217.67	228.56
Payables Turnover	11.9	6.89	24.13	22.2	1.69	1.61
Research And Ddevelopement To Revenue	2.09	1.34	0.005412	0.006701	0.47	0.44
Cash Per Share	2.46	5.72	8.5	57.81	68.13	71.54
Pocfratio	(32.18)	(1.2K)	62.17	2.51	4.32	4.53
Interest Coverage	(105.66)	(1.27)	2.8K	668.93	87.39	83.02
Capex To Operating Cash Flow	(0.36)	(6.34)	0.17	0.0268	0.13	0.14
Pfcf Ratio	(23.7)	(158.75)	75.19	2.58	4.97	5.22
Days Payables Outstanding	30.68	53.01	15.13	16.44	215.42	226.19
Income Quality	1.11	0.0924	0.0591	1.05	4.53	4.76
Roe	(0.36)	0.0111	0.87	0.47	0.046	0.0437
Ev To Operating Cash Flow	(29.92)	(1.1K)	60.61	1.51	2.19	2.3
Pe Ratio	(35.66)	1.0K	5.37	3.62	24.93	23.68
Return On Tangible Assets	(0.25)	0.007053	0.66	0.41	0.0426	0.0554
Ev To Free Cash Flow	(22.03)	(148.95)	73.3	1.55	2.52	2.64
Earnings Yield	(0.028)	9.68E-4	0.19	0.28	0.0401	0.0487
Intangibles To Total Assets	0.11	0.0705	0.0128	0.009438	0.0497	0.0881
Net Debt To E B I T D A	2.96	9.23	(0.0927)	(1.1)	(10.52)	(10.0)
Current Ratio	4.05	2.75	4.33	7.43	9.43	9.9
Tangible Book Value Per Share	1.91	5.13	47.92	81.53	78.64	82.57
Graham Number	6.67	2.91	215.09	268.18	84.75	66.44
Shareholders Equity Per Share	2.33	5.83	48.74	82.43	83.35	87.52

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

RSI	Rush Street Interactive
OKTA	Okta Inc
BAC	Bank of America

Additional Tools for BioNTech Stock Analysis

When running BioNTech's price analysis, check to measure BioNTech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioNTech is operating at the current time. Most of BioNTech's value examination focuses on studying past and present price action to predict the probability of BioNTech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioNTech's price. Additionally, you may evaluate how the addition of BioNTech to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Price To Sales Ratio	Dividend Yield
Ptb Ratio	Days Sales Outstanding
Book Value Per Share	Free Cash Flow Yield
Invested Capital	Operating Cash Flow Per Share
Average Payables	Stock Based Compensation To Revenue
Capex To Depreciation	Pb Ratio
Ev To Sales	Free Cash Flow Per Share
Roic	Inventory Turnover
Net Income Per Share	Days Of Inventory On Hand
Payables Turnover	Sales General And Administrative To Revenue
Average Inventory	Research And Ddevelopement To Revenue
Capex To Revenue	Cash Per Share
Pocfratio	Interest Coverage
Payout Ratio	Capex To Operating Cash Flow
Pfcf Ratio	Days Payables Outstanding
Net Current Asset Value	Income Quality
Roe	Tangible Asset Value
Ev To Operating Cash Flow	Pe Ratio
Return On Tangible Assets	Ev To Free Cash Flow
Earnings Yield	Intangibles To Total Assets
Net Debt To E B I T D A	Current Ratio
Tangible Book Value Per Share	Receivables Turnover
Graham Number	Shareholders Equity Per Share
Debt To Equity	Capex Per Share
Graham Net Net	Average Receivables
Revenue Per Share	Interest Debt Per Share
Debt To Assets	Enterprise Value Over E B I T D A
Short Term Coverage Ratios	Price Earnings Ratio
Operating Cycle	Price Book Value Ratio
Price Earnings To Growth Ratio	Days Of Payables Outstanding
Dividend Payout Ratio	Price To Operating Cash Flows Ratio
Price To Free Cash Flows Ratio	Pretax Profit Margin
Ebt Per Ebit	Operating Profit Margin
Effective Tax Rate	Company Equity Multiplier
Long Term Debt To Capitalization	Total Debt To Capitalization
Return On Capital Employed	Debt Equity Ratio
Ebit Per Revenue	Quick Ratio
Dividend Paid And Capex Coverage Ratio	Net Income Per E B T
Cash Ratio	Cash Conversion Cycle
Operating Cash Flow Sales Ratio	Days Of Inventory Outstanding
Days Of Sales Outstanding	Free Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage Ratios	Price To Book Ratio
Fixed Asset Turnover	Capital Expenditure Coverage Ratio
Price Cash Flow Ratio	Enterprise Value Multiple
Debt Ratio	Cash Flow To Debt Ratio
Price Sales Ratio	Return On Assets
Asset Turnover	Net Profit Margin
Gross Profit Margin	Price Fair Value
Return On Equity

BioNTech Historical Financial Ratios

About BioNTech Financial Ratios Analysis

BioNTech Financial Ratios Chart

Price To Sales Ratio

Dividend Yield

Invested Capital

Ev To Sales

Return On Tangible Assets

BioNTech fundamentals Correlations

BioNTech Account Relationship Matchups

High Positive Relationship

High Negative Relationship

BioNTech fundamentals Accounts

Also Currently Popular

Additional Tools for BioNTech Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Ev To Sales	+ 1.0	Price To Sales Ratio
Payout Ratio	+ 1.0	Dividend Yield
Pb Ratio	+ 1.0	Ptb Ratio
Free Cash Flow Per Share	+ 1.0	Operating Cash Flow Per Share
Roe	+ 0.99	Roic
Operating Cash Flow Per Share	+ 0.98	Free Cash Flow Yield

Pb Ratio	- 0.97	Capex To Depreciation
Capex To Depreciation	- 0.97	Ptb Ratio
Roe	- 0.96	Pb Ratio
Roe	- 0.96	Ptb Ratio
Payout Ratio	- 0.94	Days Of Inventory On Hand
Days Of Inventory On Hand	- 0.94	Dividend Yield